Open beta · everything is free with an account while we build. Founding accounts get preferred pricing when paid plans arrive. Create yours →
SH

STEPHEN HOLLAND

Registered · LDAActive

At a glance

Works on
Professional highlights appear here once this profile is claimed. Claim it →

Background

Career
Washington, DC · current
Government experience
Senior Health Counsel
Health Counsel - House Energy and Commerce Committee (Rep. Frank Pallone); Counsel, Legislative Assistant - Rep. Kurt Schrader
Covered official positions, as disclosed on federal filings

The past 12 months

Clients
8
past 12 months
Filings
9
past 12 months
Agencies contacted
SENATEHOUSE OF REPRESENTATIVESCommerce, Dept of (DOC)Food & Drug Administration (FDA)Health & Human Services, Dept of (HHS)State, Dept of (DOS)U.S. Trade Representative (USTR)

Specific issues

Issues related to cell and gene therapy and radioligand therapies Pharmaceutical pricing Issues related to the development of therapies for rare diseases 340B Drug Discount Program Supply chain issues affecting pharmaceutical products Implementation of the Inflation reduction Act Pharmaceutical innovation PBM policy issues HR 1672 The Maintaining Investments in New Innovations (MINI) Act Intellectual property Issues Tariff issues affecting the pharmaceutical industry EPIC Act Most Favored Nation (MFN) policy
Health Issues · 2026 Q1
Outreach regarding cell therapies for autoimmune diseases.
Pharmacy · 2026 Q1
Issues related to biotechnology legislation Diagnostic tests Clinical trial issues Issues related to supply chain
Health Issues · 2026 Q1
Issues affecting healthcare manufacturing including supply chain, intellectual property, international trade, and tariffs.
Manufacturing · 2026 Q1
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages. Pharmaceutical tariffs
Health Issues · 2026 Q1
NIH Federal grant issues FY27 Appropriations Facilities and Administration issues Issues related to Dept. of Education negotiated rulemaking on P.L. 119-21 (H.R. 1) Commerce, Justice, Science (H.R. 5342; S. 2354) Labor-HHS (H.R. 5304; S. 2587)
Education · 2026 Q1

Clients

2026 · 1 filing
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta
2026 · 1 filing
$██,███ / qtrFree in beta
$██,███ / qtrFree in beta

Sources

This profile is built from the public record: filings in the U.S. Senate Lobbying Disclosure Act system. lda.senate.gov ↗

Recent filings9
2026 Q1
NOVARTIS
Q1lda.gov →
2026 Q1
KYVERNA THERAPEUTICS, INC.
Q1lda.gov →
2026 Q1
LONZA GROUP AG
Q1lda.gov →
2026 Q1
ELI LILLY AND COMPANY
Q1lda.gov →
2026 Q1
BAYLOR COLLEGE OF MEDICINE
Q1lda.gov →
2026 Q1
CARDINAL HEALTH, INC.
Q1lda.gov →
2026 Q1
NOVAVAX, INC.
Q1lda.gov →
2026 Q1
PIERRE FABRE PHARMACEUTICALS INC.
Q1lda.gov →
2026 Q1
KYVERNA THERAPEUTICS, INC.
RRlda.gov →